These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 19707030)

  • 1. Combined intravitreal pharmacosurgery in patients with occult choroidal neovascularization secondary to wet age-related macular degeneration.
    Koss MJ; Scholtz S; Haeussler-Sinangin Y; Singh P; Koch FH
    Ophthalmologica; 2010; 224(2):72-8. PubMed ID: 19707030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravitreal bevacizumab for treatment-naïve subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Furino C; Boscia F; Recchimurzo N; Besozzi G; Cardascia N; Sborgia L; Niro A; Sborgia C
    Acta Ophthalmol; 2009 Jun; 87(4):404-7. PubMed ID: 18782335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
    Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S
    BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study.
    Costagliola C; Romano M; Corte MD; Perrotta R; Menzione M; Rinaldi M; Semeraro F; Parmeggiani F
    Retina; 2009 Oct; 29(9):1227-34. PubMed ID: 19934817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
    Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I
    Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients.
    Pedersen KB; Sjølie AK; Møller F
    Acta Ophthalmol; 2009 Nov; 87(7):714-9. PubMed ID: 19094171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration.
    Tao Y; Jonas JB
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):207-12. PubMed ID: 20415625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of core vitrectomy in the treatment of age-related macular degeneration.
    Schramm K; Mueller M; Koch FH; Singh P; Kohnen T; Koss MJ
    Acta Ophthalmol; 2014 Aug; 92(5):465-72. PubMed ID: 24690440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combined pharmacosurgery as treatment for diabetic macular edema: core pars plana vitrectomy and intravitreal injection of bevacizumab and triamcinolone].
    Naser H; Koss MJ; Singh P; Koch F
    Klin Monbl Augenheilkd; 2011 Oct; 228(10):910-4. PubMed ID: 21997827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of photodynamic therapy alone or combined with posterior subtenon triamcinolone acetonide or intravitreal bevacizumab on choroidal hypofluorescence by indocyanine green angiography.
    Hatta Y; Ishikawa K; Nishihara H; Ozawa S; Ito Y; Terasaki H
    Retina; 2010 Mar; 30(3):495-502. PubMed ID: 19996828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
    Chan WM; Lai TY; Liu DT; Lam DS
    Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization.
    Forte R; Cennamo G; Finelli M; Cesarano I; D'Amico G; De Crecchio G; Cennamo G
    Acta Ophthalmol; 2010 Dec; 88(8):e305-10. PubMed ID: 20946332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year safety and visual acuity results of epimacular 90 strontium/90 yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Avila MP; Farah ME; Santos A; Carla L; Fuji G; Rossi J; Nau J
    Retina; 2012 Jan; 32(1):10-8. PubMed ID: 21817963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors.
    Veritti D; Sarao V; Lanzetta P
    J Ocul Pharmacol Ther; 2013 May; 29(4):437-41. PubMed ID: 23215753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
    Spaide RF; Laud K; Fine HF; Klancnik JM; Meyerle CB; Yannuzzi LA; Sorenson J; Slakter J; Fisher YL; Cooney MJ
    Retina; 2006 Apr; 26(4):383-90. PubMed ID: 16603955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
    Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
    Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.